Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group
about
The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage diseasePediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.The Evolving Role of Radiotherapy in Early Stage Hodgkin's Lymphoma.Use of appropriate initial treatment among adolescents and young adults with cancer.Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031Coronary artery disease detected by coronary computed tomography angiography in adult survivors of childhood Hodgkin lymphomaThe impact of protocol assignment for older adolescents with hodgkin lymphomaPediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risksThe role of radiotherapy in Hodgkin's lymphoma: what has been achieved during the last 50 years?Omitting or reducing radiotherapy in childhood or adolescence Hodgkin Lymphoma.Historical trends in the use of radiation therapy for pediatric cancers: 1973-2008.Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral ImmunotherapyBalancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.Prognostic Factors and a New Prognostic Index Model for Children and Adolescents with Hodgkin's Lymphoma Who Underwent Autologous Hematopoietic Stem Cell Transplantation: A Multicenter Study of the Turkish Pediatric Bone Marrow Transplantation StudyChildren's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.Modern management of lymphocyte-predominant Hodgkin lymphoma.Controversies in the role of radiotherapy in the treatment of pediatric Hodgkin lymphoma.Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology GroupCurrent approaches in the management of low risk Hodgkin lymphoma in children and adolescents.Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.The evolving role of radiation therapy in pediatric Hodgkin's disease.Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients.Management of Hodgkins Lymphoma: ICMR Consensus Document.Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group.Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma.Treatment of Hodgkin's lymphoma in childhood and adolescence without radiotherapy.Pediatric Hodgkin Lymphoma: on the road to a 'radiotherapy-free' cure rate?-Commentary on a report on final results of the Multinational Trial GPOH-HD95.Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.Late mortality, secondary malignancy and hospitalisation in teenage and young adult survivors of Hodgkin lymphoma: report of the Childhood/Adolescent/Young Adult Cancer Survivors Research Program and the BC Cancer Agency Centre for Lymphoid Cancer.Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial.Effect of chemotherapy alone with adult chemotherapy regimens on prognosis of children and adolescents with Hodgkin's disease.Pulmonary outcomes in patients with Hodgkin lymphoma treated with involved field radiation.Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma.Hodgkin Lymphoma: Differences in Treatment Between Europe and the United States/North America: Evolving Trends in Protocol Therapy.Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes.End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making
P2860
Q26858893-F74A8B5C-17D0-419E-B06A-AD11D0778C08Q30248284-73054022-CF2E-421A-B721-A205E4BDB02CQ33778385-2D2B9678-FADF-4198-991A-DD78A95CF559Q34354175-89385948-9440-41DE-BCD4-B295F1342542Q34451778-B13793CC-2134-4AB2-A4BC-F8DE45783838Q34459086-B2DE96D5-001B-4ACE-BB87-4EF477D19128Q34582650-ADF8C5DE-9B8A-41A7-B4C5-583F155AC804Q34640709-A662144E-CF49-472B-B609-F9D0F76B7B06Q35091669-D6116C97-EB98-450D-961B-22DA14730FC8Q36508230-90FCE878-A913-487B-B942-F90FF9236900Q36795804-BF27E39D-9630-4950-A2E4-3579089EFAF2Q36928875-CD06A09E-A2E1-40D8-B909-B2F24A01F99AQ37383554-5BF3E9E0-7B5C-4DD3-866D-ED8CFF325980Q37412853-893A2697-7F12-4828-A1E6-8312CABDEB21Q37548240-547E459E-51E1-4DBE-8AC3-A3640E39658BQ38068839-C1A120AB-9C1F-4EC9-984E-6B3D5EB88ED8Q38080591-56F1AAC7-4D77-457E-A3A1-AF3BC222AF96Q38131410-1FD09F1B-8475-466A-AAC1-F9EA4C73F95CQ38301247-75AEA8BC-AC9F-4708-B518-F4D4F09C4787Q38396485-7945986D-540B-4E3B-B117-4FE013B2E2C5Q38817696-2576BEB5-7220-48E5-A561-75811B06FA03Q38823537-C7F2D45A-3E69-428E-8121-54256BED556AQ39129713-FCAF7F43-A947-4213-9EAB-01C5311554AEQ39208309-3D97E2EE-7B61-410B-B295-393CA6362981Q39244757-1005C9E8-693B-4857-AB59-D74A823AD4EBQ39456225-0552D587-2C8D-46BF-8D72-A0537589DB00Q40033077-A526BE86-96FE-4545-8F9B-87AB502A7047Q40033092-76E16020-1F80-4D6F-9799-DAE1BE230EEBQ40044179-E1F10F1B-8AB5-4252-9299-EF5DF21EC82BQ40148445-0DC5A6B7-9F9C-4188-AF3B-501217253244Q40465014-25DCDD21-620F-4B40-A4A3-EC8680B910A3Q40762228-64C01BDA-E3D8-4A26-B8E0-A36B319C60ADQ46213781-7B0CE724-BBE9-4B25-8869-4A9E8CDF4DA4Q47639244-ACDA44F6-2529-47E4-B6B0-23A2B5AD66BCQ50054777-BE73A64D-13C4-427F-8343-B83B268C8038Q52715715-DA05511A-9B3A-42E4-9517-5CA0579310F1Q56516736-98FD47B9-622D-487E-87CC-A70FE1D17E4A
P2860
Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Long-term results of CCG 5942: ...... the Children's Oncology Group
@ast
Long-term results of CCG 5942: ...... the Children's Oncology Group
@en
type
label
Long-term results of CCG 5942: ...... the Children's Oncology Group
@ast
Long-term results of CCG 5942: ...... the Children's Oncology Group
@en
prefLabel
Long-term results of CCG 5942: ...... the Children's Oncology Group
@ast
Long-term results of CCG 5942: ...... the Children's Oncology Group
@en
P2093
P2860
P356
P1476
Long-term results of CCG 5942: ...... the Children's Oncology Group
@en
P2093
Gerald S Gilchrist
James Nachman
John Thomson
Kara M Kelly
Marshall E Kadin
Philip Herzog
Raymond J Hutchinson
Richard Sposto
Suzanne L Wolden
P2860
P304
P356
10.1200/JCO.2011.41.1819
P407
P577
2012-05-29T00:00:00Z